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Abstract
Background: Age- and sex-specific reference intervals are an important prerequisite for interpreting
thyroid hormone measurements in children. However, only few studies have reported age- and sex-
specific pediatric reference values for TSHbasal (TSH), free T3 (fT3), and free T4 (fT4) so far. Reference
intervals are known to be method- and population-dependent. The aim of our study was to establish
reference intervals for serum TSH, fT3, and fT4 from birth to 18 years and to assess sex differences.
Methods: 2,194 thyroid hormone tests obtained from a hospital-based pediatric population were
included into our retrospective analysis. Individuals with diagnoses or medications likely to affect
thyroid function were primarily excluded, as well as the diagnostic groups, if different from the
purely healthy subgroup (n = 414). Age groups were ranging from 1 day to 1 month, 1 – 12 months,
and 1 – 5, 6 – 10, 11 – 14, and 15 – 18 years, respectively. Levels of fT3, fT4 and TSH were
measured on Advia
® Centaur™ automated immunoassay system.
Results: The final sample size for reference data creation was 1,209 for TSH, 1,395 for fT3, and
1,229 for fT4. Median and 2.5/10/25/75/90/97.5 percentiles were calculated for each age group.
Males had greater mean fT3 concentrations than females (p < 0.001). No sex-differences were
found for TSH and fT4 between age-matched serum samples. Median concentrations of fT3, fT4
and TSH were greatest during the first month of life, followed by a continuous decline with age.
Conclusion: Our results corroborate those of previous studies showing that thyroid hormone
levels change markedly during childhood, and that adult reference intervals are not universally
applicable to children. Moreover, differences of our reference intervals compared to previous
studies were observed, likely caused by different antibody characteristics of various analytical
methods, different populations or undefined geographic covariates, e.g. iodine and selenium status.
Background
Hypothyroidism in children is associated with impaired
physical and/or cognitive development. Therefore, neo-
natal screening for thyrotropin (TSH) values has been
established in the majority of developed countries to
timely diagnose and treat congenital hypothyroidism, in
order to prevent severe mental retardation. During
childhood and adolescence, basal TSH levels are
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diagnosing hypothyroidism and hyperthyroidism, and
for the monitoring of thyroid replacement therapy.
Nevertheless, measurement of free T4 (fT4) is indis-
pensable to confirm these diagnoses, since it directly
reflects hormone production by the thyroid gland [1].
Measurement of free T3 (fT3) only indirectly reflects
thyroid hormone production but may provide addi-
tional information, since most of fT3 is produced by
intracellular conversion by the deiodinases.
Despite their importance for interpreting individual
results in clinical practice, pediatric reference values for
thyroid function are scarce and published normative
data often comprise only small numbers of patients
[2-7]. Moreover, reference values vary considerably as
they are population- and assay- specific. Significant
variations of thyroid hormone levels during growth
have been observed although, in contrast to a common
misconception, pubertal development does not affect
the concentration of thyroid hormones in children [3].
Data are inconsistent concerning sex differences. Biolo-
gical variables such as nutrition and lifestyle may also
influence thyroid function.
The aims of our study were 1) to establish age-specific
reference intervals for serum concentrations of TSH, fT3,
and fT4 in healthy children, 2) to assess sex differences in
thyroid function, and 3) to compare our results to
previously published reference data.
Methods
Subjects
Between July 2002 and October 2003 routine results of
serum TSH, fT3, and fT4 were collected from existing
laboratory data of 2,194 serum samples from a hospital
based population of children aged 1 day – 18 years. The in-
and out clinic patients had been admitted to the pediatric
department of the Medical University Innsbruck for a
variety of reasons. Subjects were sub-grouped according
to age, ranging from 1 day to 1 month, 1 – 12 months, and
1 – 5, 6 – 10, 11 – 14, and 15 – 18 years, respectively.
Classification of age groups was primarily based on those
of previously published studies to facilitate reliable
comparison of the results, and also specifically according
to the age-related course of the obtained values. Two or
more samples were taken from 410 patients, 1,085 patients
had only one serum sample taken. All procedures were
done in accordance with the Declaration of Helsinki.
Data were collected routinely within the setting of
clinical practice according to standard procedures. The
parents of the children gave their informed consent. No
further measures were taken beyond clinical practice.
Classification of the patients in diagnostic categories was
done using the International Classification of Diseases
(ICD-10) codes. Children with conditions or concomi-
tant medications likely to affect thyroid function were
excluded from the reference group [8]. Also patients with
eating disorders, with pituitary disease or chromosomal
anomalies were not included in the analysis. Patients
presenting a deviation in height or weight were
identified at the clinical examination and classified as
normal variants of growth (ICD E34.3 and E34.4)
including familial or constitutional factors. All diagnos-
tic groups have been included in a separate Excel file
(additional material). Each diagnostic group was statis-
tically evaluated in comparison to Z00.0 (n = 414;
general examination and investigation of persons with-
out complaint and reported diagnosis) using the one
way ANOVA post-hoc analyses (data not shown). Serum
samples from patients having the following ICD-10
diagnostic codes indicating thyroid dysfunction were
excluded a-priori (n = 665): Congenital hypothyroidism
with and without diffuse goiter (E03.0, E03.1), other
non toxic goiter (E04.0 – E04.9), dyshormonogenetic
goiter (E07.1), thyrotoxicosis (E05.0 – E05.9), autoim-
mune thyroiditis and unspecified thyroiditis (E06.3,
E06.9), any neoplasm of the thyroid gland (C73 and
D44.0), post procedural hypothyroidism (E89.0), and
other specified or unspecified hypothyroidism (E03.8,
E03.9).
Methods
Analyses of TSH, fT3, and fT4 from undiluted serum
samples of children and adolescents were performed on
an automated immunoassay system (Advia
® Centaur™,
Bayer Health Care Diagnostika, Vienna, Austria) using a
direct chemiluminiscence detection system according to
the manufacturer's instructions [9, 10]. TSH was ana-
lyzed in a two-site solid-phase format, whereas analysis
of fT3 and fT4 was performed in a competitive assay. The
intraassay coefficients of variation for TSH, fT3, and for
fT4 were < 8.7%, < 3.5%, and < 8.1% respectively. The
reference values on adult patients using this immunoas-
say system have recently been published in BMC
Endocrine Disorders and Thyroid [11, 12].
Statistical analysis
In addition to the selection criteria for the total reference
group detailed above, serum values of TSH, fT3, and fT4
in each diagnostic group were also compared to the
sub-group of primarily healthy children and adolescents
(n = 414) using ANOVA and post-hoc Tukey's test.
Groups that were not statistically different were pooled
with the healthy reference group. Values of thyroid
hormones were tested for their normal distribution.
Because of the strong right-tailed skewed distribution of
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14]. Comparison between age-groups was performed
using the unifactorial ANOVA test and post-hoc Tukey's
test. Further post-hoc comparisons of mean values
between age groups and sexes were assessed using the
Student's t-test. Correlation analysis was performed
using the Pearson method.
Two-tailed values of p < 0.05 were considered statistically
significant. Medians and percentiles (2.5
th to 97.5
th)f o r
each variable were determined and taken as the reference
interval. Statistical Package for Social Sciences (SPSS Inc.,
Chicago, IL, USA, version 12.0) was used for statistical
analysis and creation of percentiles.
Results
TSH
The final sample size for the evaluation of TSH was
1,209. No difference was found between serum TSH
concentrations of male (n = 636; 52.6%) and female (n =
573; 47.4%) children and adolescents (p = 0.689) of all
age groups. Therefore, both sexes were combined for the
calculation of percentiles. Log transformation was done
before analysis because of the significant right-tailed
skewed distribution of the TSH values.
The 97.5
th percentile was significantly higher in the age
group of 0 – 1 month compared to all other age groups.
TSH values decreased continuously with age, particularly
during the first year of life. The 2.5
th percentile was lower
in the first month compared to the first year of life and
subsequently alsodecreasedwithage(figure1andtable1).
Variance for TSH was greatest in the first month of life
and became narrower with increasing age (0–1m o n t h :
var = 15.04; 1–12 months: var = 3.55; 1–5y e a r s :v a r=
2.96; 6–10 years: var = 1.46; 11–14 years: var = 1.08;
15–18 years: var = 0.98). A longitudinal sub-group of
32 patients with repeated evaluation of thyroid
function showed initially elevated TSH, but normal
fT3 and fT4 levels, which decreased and normalized
spontaneouslywithin3to6monthswithouttreatment.The
age of these patients corresponds to that of the whole group
(1 to 18 years of age). The cause for the initial elevation of
TSH was not found. The follow-up evaluations discarded
the presence of subclinical hypothyroidism so that their
TSH values were included. The initially elevated TSH levels
were detected as outliers.
fT3
The final number of samples for fT3 was 1,395. Results for
fT3 were normally distributed. As expected, the median
concentrations of fT3 were greatest in the age group up to
one month, thereafter showing a continuous decline with
age (p < 0.001; r = -0.266 for females and r = -0.196
for males), except for males 1 – 5 years and females 6 – 10
years. Males had greater (p < 0.001) mean fT3 concentra-
tions (n = 824; 59.1%) than females (n = 571; 40.9%). The
decrease of the 2.5
th percentile was more distinct compared
to the 97.5
th percentile (figures 2 and 3, table 2).
Figure 1
Reference intervals for TSH of age groups listed in
table 2. The central 95% range (2.5
th,2 5
th,5 0
th,7 5
th,a n d
97.5
th percentiles) is shown. Due to resolution reasons lines
start at zero, although no samples were taken within the first
hours after birth.
Table 1: Percentiles for TSH (mU/L) of children and adolescents in different age groups
Age n percentiles
2.5 10 25 50 75 90 97.5
0 – 1 months 22 0.70 1.00 1.78 3.50 5.03 9.34 18.10
1–12 months 42 1.12 1.53 1.88 2.85 4.43 6.81 8.21
1–5y e a r s 218 0.80 1.30 1.78 2.70 3.70 4.80 6.26
6–10 years 315 0.80 1.20 1.70 2.30 3.10 3.80 5.40
11–14 years 355 0.70 1.10 1.60 2.10 2.80 3.60 4.61
15–18 years 233 0.50 0.94 1.30 1.70 2.35 3.30 4.33
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The final sample size was 1,229 for fT4 (638 males =
51.9%; 591 females = 48.1%). No sex-difference of fT4
values were found in any age group (p = 0.268) and
results were normally distributed. Values for fT4 showed
a significant negative correlation with age (p < 0.001;
r = -0.122). Variance for fT4 was greatest in the first
month of life and then became narrower with age (0–1
month: var = 45.91; 1–12 months: var = 8.60; 1–5y e a r s :
var = 7.68; 6–10 years: var = 6.13; 11–14 years: var =
8.20; 15–18 years: var = 8.08) (figure 4). The 97.5
th
percentile showed a peak value of 30.5 pmol/L during
the first month of the life and subsequently quite steady
concentrations between 20 and 22.5 pmol/L. The 50
th
percentile of fT4 was also greatest in the first month of
life with a rapid decrease during the first year of life and
subsequently remained constant until the age of 18 years
(table 3).
Discussion
This study provides new pediatric reference intervals for
TSH, fT3, and fT4 for healthy Austrian children and
adolescents using the Advia
® Centaur™ assay. Adult
reference values for thyroid function are well established,
although the upper limit of normal TSH values is also
currently under discussion [13, 15-19]. Recently adult
reference values for thyroid function parameters using
the Advia
® Centaur™ assay have been defined by our
study group [11, 12]. In children and adolescents,
reliable age- and sex-specific reference intervals are an
indispensable prerequisite to interpret individual
Figure 2
The central 95% range for fT3 in females (2.5
th,2 5
th,
50
th,7 5
th,a n d9 7 . 5
th percentiles) is shown.
Figure 3
The central 95% range for fT3 in males (2.5
th,2 5
th,
50
th,7 5
th,a n d9 7 . 5
th percentiles) is shown.
Table 2: Percentiles for fT3 (pmol/L) of children and adolescents in different age groups.
Age Sex n percentiles
2.5 10 25 50 75 90 97.5
0 – 1 months f5 5.00 5.00 5.40 6.60 7.30 7.50 7.50
m9 4.60 4.60 5.70 6.30 6.90 10.10 10.10
1–12 months f1 4 4.30 4.50 5.63 6.15 7.03 7.50 7.60
m1 3 4.30 4.74 5.65 6.20 6.70 7.38 7.50
1–5y e a r s f 108 4.25 4.80 5.50 6.15 6.58 7.11 7.61
m 111 3.96 5.32 5.70 6.30 6.70 7.48 8.14
6–10 years f 163 4.21 5.10 5.50 6.20 6.60 7.00 7.58
m 219 4.05 5.20 5.70 6.10 6.50 7.10 7.50
11–14 years f 180 3.51 4.90 5.40 5.90 6.30 6.80 7.30
m 252 4.63 5.20 5.60 6.00 6.40 6.80 7.20
15–18 years f9 8 3.50 4.48 4.80 5.30 5.83 6.50 6.90
m 211 4.20 5.00 5.40 5.80 6.20 6.60 7.47
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values are population and method-dependent [20, 21].
Thus, a series of pediatric thyroid reference data have
been published using different analytical methods and
antibody characteristics with variable subject numbers
[2-7]. To our knowledge, only one, smaller study in
children and adolescents used the Advia
® Centaur™
assay, which is widely used in clinical laboratories [4].
We are well aware of methodological advances in the
determination of free thyroid hormones based on the
technique of isotope dilution tandem mass spectrometry
[22-29] which correlates better with equilibrium dialysis
procedures [30]. In spite of this advantage we still advocate
the used of an immunoassay procedure as we have done in
this study. In previous publications we have evaluated
extensively the clinical applicability of such a system for the
determination of reference values for adults [11]. On
practical terms, the immunoassay procedure with the Advia
Centaur
® [5] will deliver results for fT3, fT4, TSH,
thyroglobulin antibodies, and thyroid peroxidase antibo-
dies within 20 minutes that meets requirements for clinical
use [9, 31]. These practical conveniences outweighs the
need for a high capital expenditure [32].
One limitation of our study is that it comprises a
hospital-based population. Ideally, reference intervals
should be determined using blood samples obtained
from a large cohort of healthy subjects. However, due to
ethical and practical considerations in children, reference
interval determination often relies on large hospital
databases, which, by applying appropriate selection
criteria, ensure sufficient number of samples [33, 34].
The reference groups in this and other similar studies are
not strikingly population based and results might
slightly diverge. We addressed this concern by excluding
all subjects with diagnoses and concomitant medications
that might affect thyroid function. By this the subjects
fulfilled the criteria for a healthy population as is
foreseen in the category ICD10 Z00.
Median concentrations of all thyroid parameters mea-
sured were highest in the first month of life and
subsequently decreased with age, apart from fT3 values
of males aged 1 – 5 years and females aged 6 – 10 years.
Overall, our reference data concur with those of previous
studies in pediatric cohorts using various analytical
methods. Slight differences of our reference intervals
compared to previous studies (tables 4, 5, 6) might be
explained by different analytical assays, differences in
ethnicity, population or geographic derived covariates
such as lifestyle, salt iodination, and nutrition. The last
evaluation of iodine status done by our study group with
adult patients in 2000 showed a mean value of urinary
excretion of 120 μg iodine/gr creatinine (R. Moncayo,
unpublished data analyzed 2002).
Significant sex differences were observed only for fT3 in
our study cohort. Interestingly, Hübner et al. found sex-
specific effects also on fT3 residuals, but only within the
age group 11 – 14 using the same Advia
® Centaur™
Table 3: Percentiles for fT4 (pmol/L) of children and adolescents in different age groups.
Age n percentiles
2.5 10 25 50 75 90 97.5
0 – 1 months 23 8.50 8.98 13.50 20.10 24.70 28.48 30.50
1–12 months 45 9.17 13.10 14.00 15.50 17.20 19.22 25.28
1–5Y e a r s 229 10.45 12.80 14.15 15.70 17.90 19.70 22.35
6–10 Years 327 10.60 12.80 14.40 15.90 17.30 18.90 20.90
11–14 Years 364 10.40 12.15 13.40 15.20 16,80 19.05 21.36
15–18 Years 233 10.57 11.74 13.50 15.20 16.90 18.80 22.62
Figure 4
Age-related reference values for fT4 (both sexes).
The central 95% range (2.5
th,2 5
th,5 0
th,7 5
th,a n d9 7 . 5
th
percentiles) is shown. Due to resolution reasons lines start
at zero, although no samples were taken within the first
hours after birth.
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(page number not for citation purposes)Table 4: Comparison of our TSH reference intervals to previously published reference intervals (2.5, 50 and 97.5%) of different age groups.
Soldin et al., 1995
Abbott IMx
®
Zurakowski et al.,
1999 DELFIA
®
Elmlinger et al., 2001
Immulite
®
Djemli et al., 2004
Access 2
®
Hübner et al., 2002
Advia Centaur
®
Kapelari et al., Advia
Centaur
®
Age
TSH [mU/L] [mU/L] [mU/L] [mU/L] [mU/L] [mU/L]
n=5 3 3 n=5 , 5 5 8 n=7 6 2 n=7 0 6 n=4 6 0 n=1 , 2 0 9
1d– 7d F: 0.72 – 13.1 n.d. 1.79 – 4.63 – 9.69 F: 1.5 – 3.3 – 6.5 0.13 – 9.23
a 0.75 – 3.50 – 16.89
8d –15 d M: 0.52 – 16.0 n.d. 1.80 – 3.71 – 7.97 M: 0.7 – 2.4 – 9.8 0.16 – 8.48
b
15 d – 1m n.d. n.d.
1 – 12 m 0.8 – 2.2 – 6.3 F: 1.0 – 2.4 – 5.7 0.3 – 1.73 – 5.88
c 1.30 – 2.85 – 7.09
1 – 2y 0.63 – 2.04 – 4.12 M: 0.7 – 2.1 – 5.9
2 – 3y F: 0.46 – 8.1 F: 0.7 – 2.0 – 5.9 n.d. 0.42 – 1.98 – 4.79 1.00 – 2.70 – 5.42
3 – 4y M: 0.55 – 7.1 M: 0.7 – 2.1 – 6.0 n.d.
4 – 5y 0.53 – 1.60 – 2.94 n.d.
5 – 6y F: 0.36 – 5.8 n.d.
7 – 8 M: 0.37 – 6.0 F: 0.6 – 1.8 – 5.1 0.80 – 1.86 – 3.48 n.d. 0.48 – 1.87 – 4.67 0.90 – 2.30 – 4.40
9 – 10 M: 0.7 – 1.9 – 5.4 0.85 – 2.00 – 3.50 F: 0.9 – 2.0 – 4.0
M: 1.0 – 1.9 – 3.7
11 0.85 – 1.90 – 3.33
12 F: 0.5 – 1.5 – 4.4 0.86 – 1.90 – 3.21 F: 0.7 – 1.7 – 3.4 0.53 – 1.78 – 4.58 0.90 – 2.10 – 4.10
13 M: 0.6 – 1.7 – 4.9 0.80 – 1.81 – 3.08 M: 0.8 – 1.8 – 3.9
14 0.76 – 1.70 – 2.83
15 0.70 – 1.56 – 2.55
16 0.64 – 1.54 – 2.51 F: 0.6 – 1.5 – 3.7 0.56 – 2.00 – 4.53 0.70 – 1.70 – 3.93
17 F: 0.5 – 1.3 – 3.9 0.62 – 1.51 – 2.42 M: 0.7 – 1.4 – 2.8
18 – 19 M: 0.5 – 1.6 – 4.4 0.52 – 1.36 – 2.36 n.d.
a 1d– 3d
b 4d– 30 d
c 61 d – 12 m
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)analyzer system [4]. Soldin et al [5] reported sex specific
reference ranges without testing for statistical signifi-
cance, and Djemli et al. [6] found significant differences
between girls and boys on fT4 residuals only within the
age group 15 – 17, whereas Elmlinger et al. [3] did not
find any sex differences between sexes, also by adjusting
for pubertal stage. The reason for these inconsistent
findings remains unclear. Further studies in children and
adolescents are needed to investigate, whether there is a
significant influence of sex on thyroid hormone levels
justifying distinct reference intervals.
Interestingly, in the longitudinal subgroup of 32
children with initially elevated TSH levels in the first
serum sample, TSH decreased to normal without
treatment within 3 – 6 months. Decision not to treat
these children was based on the clinical status, since it
did not correspond to subclinical or clinical hypothyr-
oidism even though the initial TSH value was elevated.
This phenomenon suggests the presence of transient
benign conditions affecting thyroid function. We there-
fore recommend that patients with initially elevated
TSH values should be retested in approximately 3 to 6
months interval, before considering replacement therapy
[35]. In addition the levels of fT3, fT4, the presence of
thyroperoxidase antibodies, and, in specific cases, the
degree of stimulated TSH elevations should be taken into
account before classifying a child or adolescent as
hypothyroid [36, 37]. Further prospective studies in
children, similar to that of Huber et al. [38] in adults, are
needed to study the spontaneous course of subclinical
hypothyroidism in children and adolescents, and to
determine risk factors for the development of overt
hypothyroidism.
Apart from the age group 15 – 18 years, differences were
observed to the published reference intervals for adult
populations, especially for TSH. Recently, some authors
argued for a reduction of the upper cut off range for TSH
to 2.5 mU/L or somewhat more moderate to 3.0 mU/L in
adults [15, 16, 39, 40]. Applying this upper range to
pediatric patients might lead to a considerable high
number of false diagnoses of hypothyroidism and result
in unnecessary lifelong replacement therapy. A similar
scenario has already been described for TSH reference
values for adults [41].
In conclusion, this study provides pediatric reference
intervals for thyroid function tests from birth to young
adulthood for a middle European population. Thyroid
hormone levels markedly change during childhood
without showing significant sex differences, except for
Table 5: Comparison of our fT3 reference intervals to previously published reference intervals (2.5, 50 and 97.5%) of different age
groups.
Soldin et al., 1995 Abbott
IMx
®
Elmlinger et al.,
2001 Immulite
®
Hübner et al., 2002 Advia
Centaur
®
Kapelari et al., Advia Cen-
taur
®
Age
fT3 [pmol/L] [pmol/L] [pmol/L] [pmol/L]
n = 1,069 n = 762 n = 460 n = 1,295
1d– 7d 2.2 – 7.4 2.76 – 6.91 – 11.67 2.32 – 8.11
a F: 5.00 – 6.60 – 7.50
8 – 15 d 2.2 – 8.4 2.84 – 5.53 – 11.86 2.40 – 7.94
b M: 4.60 – 6.30 – 10.10
15 d – 1m n.d.
1 – 12 m 3.1 – 10.6 2.72 – 5.27 – 7.30
c F: 4.30 – 6.15 – 7.60
M: 4.30 – 6.20 – 7.50
1 – 2y 3.28 – 6.08 – 11.06 3.05 – 5.63 – 6.93 F: 4.45 – 6.15 – 7.46
2 – 3y M: 4.70 – 6.30 – 7.84
3 – 4y 3.7 – 10.3
4 – 5y 3.43 – 6.57 – 10.97
5 – 6y F: 4.60 – 6.20 – 7.30
7 – 8 4.4 – 9.2 3.58 – 6.71 – 10.75 3.30 – 5.58 – 6.79 M: 4.80 – 6.10 – 7.20
9 – 10 3.72 – 6.44 – 10.87
11 3.76 – 6.13 – 9.98
12 3.76 – 5.88 – 8.86 3.46 – 5.54 – 6.7 F: 4.41 – 5.90 – 7.00
13 4.8 – 9.1 3.84 – 5.64 – 8.03 M: 4.90 – 6.00 – 7.00
14 3.81 – 5.45 – 7.28
15 3.69 – 5.16 – 6.87
16 3.61 – 4.98 – 6.88 3.57 – 5.33 – 6.65 F: 4.08 – 5.30 – 6.80
17 5.4 – 8.8 3.54 – 4.76 – 6.60 M: 4.60 – 5.80 – 7.10
18 – 19 3.52 – 4.65 – 6.30
a 1d– 3d
b 4d– 30 d
c 61 d – 12 m
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Soldin et al., 1995
Abbott IMx
®
Zurakowski et al., 1999
DELFIA
®
Elmlinger et al., 2001
Immulite
®
Djemli et al., 2004
Access 2
®
Hübner et al., 2002
Advia Centaur
®
Kapelari et al. Advia
Centaur
®
Age
fT4 [pmol/L] [pmol/L] [pmol/L] [pmol/L] [pmol/L] [pmol/L]
n = 1,173 n = 353 n = 762 n = 710 n = 460 n = 1,221
1d – 7d F: 11 – 25 n.d. 29.60 – 62.40 – 79.20 F: 11.0 – 13.6 – 22.3 10.8 – 26.8
a 8.54 – 20.10 – 30.20
M: 10 – 36
8 – 15 d F: 8 – 25 n.d. 18.00 – 42.30 – 63.60 M: 9.8 – 12.2 – 23.2 10.9 – 25.5
b
15 d – 1m M: 6 – 30 n.d. n.d.
1 – 12 m F: 11 – 24 9.5 – 19.5 – 39.5 11.10 – 19.70 – 27.30 F: 9.0 – 11.3 – 16.1 11.4 – 14.5 – 20.9
c 11.95 – 15.50 – 22.51
M: 10 – 26
1 – 2y M: 8.7 – 11.7 – 16.2
2 – 3y F: 13 – 22 9.0 – 18.4 – 37.2 n.d. 11.4 – 14.7 – 19.0 11.90 – 15.70 – 20.85
3 – 4y M: 12 – 21 n.d.
4 – 5y 12.90 – 17.30 – 23.90 n.d.
5 – 6y n.d.
7 – 8 F: 11 – 20 8.3 – 16.9 – 34.1 12.90 – 19.30 – 24.50 n.d. 11.0 – 14.2 – 18.8 11.54 – 15.90 – 19.96
9 – 10 M: 10 – 22 10.30 – 17.00 – 23.80 F: 9.6 – 11.6 – 14.5
M: 9.7 – 11.7 – 14.2
11 11.80 – 16.70 – 22.65
12 F: 10 – 19 10.40 – 16.20 – 22.91 F: 8.8 – 10.7 – 13.5 10.8 – 13.6 – 18.7 11.10 – 15.20 – 20.00
13 M: 12 – 20 7.6 – 15.5 – 31.5 8.50 – 16.50 – 22.52 M: 8.4 – 10.8 – 13.0
14 12.20 – 16.50 – 23.30
15 9.10 – 17.00 – 23.40 10.7 – 14.4 – 18.7 10.80 – 15.20 – 20.33
16 F: 11 – 19 12.90 – 16.70 – 23.30 F: 8.7 – 10.7 – 13.6
17 M: 12 – 20 7.0 – 14.1 – 28.7 11.80 – 17.40 – 22.50 M: 9.5 – 11.8 – 15.0
18 – 19 9.30 – 14.50 – 20.50 n.d.
a 1d– 3d
b 4d– 30 d
c 61 d
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)fT3. Moreover, differences of our reference intervals
compared to previous studies were observed, likely
caused by different antibody characteristics of various
analytical methods, different populations or unknown
geographic covariates. Our results argue in favor that
adult reference intervals are not universally applicable to
children. These reference intervals may serve as a tool for
the correct interpretation of individual thyroid hormone
results of children and adolescents.
Conclusion
Our results corroborate those of previous studies
showing that thyroid hormone levels change markedly
during childhood, and that adult reference intervals are
not universally applicable to children. Moreover, differ-
ences of our reference intervals compared to previous
studies were observed, likely caused by different anti-
body characteristics of various analytical methods,
different populations or undefined geographic covari-
a t e s ,e . g .i o d i n ea n ds e l e n i u ms t a t u s .
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